Vikrant Therapeutics Corporate Presentation 2023

Vikrant Therapeutics is developing novel therapeutics for metabolic and endocrine diseases, with clinical-stage programs including VK2809 (thyroid receptor-β agonist for NASH), VK2735 (GLP-1/GIP dual agonist for metabolic disorders), and VK0214 (thyroid receptor-β agonist for X-ALD). The company's pipeline demonstrates best-in-class efficacy data across metabolic disease and rare disease indications.